|
|
Stakeholder Insight: Dyslipidemia - Statins Dominate Treatment Pathway - For NowPublished by: Datamonitor Published: Oct. 5, 2005 - 204 Pages Table of Contents
List of Tables Table 1: Key changes to lipid levels between the NCEP II and NCEP III Table 2: Estimated proportion of dyslipidemia patients with co-morbid conditions and risk factors in the seven major markets, 2005 Table 3: Epidemiology overview of dyslipidemia, 2005-15 Table 4: Epidemiology figures by age for the seven major markets, 2005 Table 5: Estimated breakdown of the management of dyslipidemia in the general population by physician type, 2005 Table 6: Breakdown of dyslipidemia management across the different populations in the seven major markets, 2005 Table 7: Proportion of drug-treated patients prescribed each type of therapy in the seven major markets, 2005 Table 8: AVALON trial results Table 9: Generic price of simvastatin in the UK Table 10: TNT study results Table 11: CARDS study results Table 12: Breakdown of statin prescribing by line of therapy in the seven major markets, 2005 Table 13: Breakdown of statin prescribing by daily dose in the seven major markets, 2005 Table 14: Availability of generic statins in the seven major markets, 2005 Table 15: Proportion of overall drug-treated dyslipidemia patients prescribed each antidyslipidemic drug class as first-line therapy in the seven major markets, 2005 Table 16: Proportion of overall drug-treated dyslipidemia patients prescribed each antidyslipidemic drug class as second-line therapy in the seven major markets, 2005 Table 17: Average number of changes a patient undergoes over one year, 2005 Table 18: Change in combination therapy over the next three years in the seven major markets, 2005 Table 19: Breakdown of combination therapy by dyslipidemia sub-population in the seven major markets, 2005 Table 20: Physician ratings of factors providing incentives/disincentives for the future prescribing of new therapies as adjuncts to statins in the seven major markets, 2005 Table 21: Proportion of drug-treated dyslipidemia patients in each sub-population failing to reach target cholesterol goals in the seven major markets, 2005 Table 22: Average rating of factors influencing the prescribing of antidyslipidemic therapy in the seven major markets, 2005 Table 23: Mean ranking of preferred statin to use with ezetimibe, 2005 Table 24: Physician opinions of Vytorin, 2005 Table 25: Price comparison of Vytorin, 2005 Table 26: US physicians' opinion of Crestor, 2005 Table 27: US physician sample breakdown, 2005 Table 28: Japan physician sample breakdown, 2005 Table 29: France physician sample breakdown, 2005 Table 30: Germany physician sample breakdown, 2005 Table 31: Italy physician sample breakdown, 2005 Table 32: Spain physician sample breakdown, 2005 Table 33: UK physician sample breakdown, 2005 List of Figures Figure 1: Diagrammatic overview of the coverage of the dyslipidemia Stakeholder Insight survey, 2005 Figure 2: Breakdown of the overall dyslipidemia population in the US by diagnosis, type of dyslipidemia, disease severity and prevalence of risk factors and co-morbidities, 2005 Figure 3: Breakdown of drug therapy in the diagnosed dyslipidemia sub-populations in the US, 2005 Figure 4: Breakdown of statin therapy by compound, line of therapy, daily dose and use of brands versus generics in the US, for the overall drug treated dyslipidemia population, 2005 Figure 5: Breakdown of first- and second-line therapy by antidyslipidemic drug class in the US for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 6: Segmentation of drug-treated overall dyslipidemia population having therapy changed over a one-year period in the US for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 7: Breakdown of combination therapy by dyslipidemia sub-population in the US for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 8: Breakdown of treatment outcomes by dyslipidemia sub-population in the US, 2005 Figure 9: Breakdown of the overall dyslipidemia population in Japan by diagnosis, type of dyslipidemia, disease severity and prevalence of risk factors and co-morbidities, 2005 Figure 10: Breakdown of drug therapy in the diagnosed dyslipidemia sub-populations in Japan, 2005 Figure 11: Breakdown of statin therapy by compound, line of therapy, daily dose and use of brands versus generics in Japan, for the overall drug treated dyslipidemia population, 2005 Figure 12: Breakdown of first- and second-line therapy by antidyslipidemic drug class in Japan for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 13: Segmentation of drug-treated overall dyslipidemia population having therapy changed over a one-year period in Japan for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 14: Breakdown of combination therapy by dyslipidemia sub-population in Japan, 2005 Figure 15: Breakdown of treatment outcomes by dyslipidemia sub-population in Japan, 2005 Figure 16: Breakdown of the overall dyslipidemia population in France by diagnosis, type of dyslipidemia, disease severity and prevalence of risk factors and co-morbidities, 2005 Figure 17: Breakdown of drug therapy in the diagnosed dyslipidemia sub-populations in France, 2005 Figure 18: Breakdown of statin therapy by compound, line of therapy, daily dose and use of brands versus generics in France, for the overall drug treated dyslipidemia population, 2005 Figure 19: Breakdown of first- and second-line therapy by antidyslipidemic drug class in France for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 20: Segmentation of drug-treated overall dyslipidemia population having therapy changed over a one-year period in France for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 21: Breakdown of combination therapy by dyslipidemia sub-population in France, 2005 Figure 22: Breakdown of treatment outcomes by dyslipidemia sub-population in France, 2005 Figure 23: Breakdown of the overall dyslipidemia population in Germany by diagnosis, type of dyslipidemia, disease severity and prevalence of risk factors and co-morbidities, 2005 Figure 24: Breakdown of drug therapy in the diagnosed dyslipidemia sub-populations in Germany, 2003 Figure 25: Breakdown of statin therapy by compound, line of therapy, daily dose and use of brands versus generics in Germany, for the overall drug treated dyslipidemia population, 2005 Figure 26: Breakdown of first- and second-line therapy by antidyslipidemic drug class in Germany for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 27: Segmentation of drug-treated overall dyslipidemia population having therapy changed over a one-year period in Germany for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 28: Breakdown of combination therapy by dyslipidemia sub-population in Germany, 2005 Figure 29: Breakdown of treatment outcomes by dyslipidemia sub-population in Germany, 2005 Figure 30: Breakdown of the overall dyslipidemia population in Italy by diagnosis, type of dyslipidemia, disease severity and prevalence of risk factors and co-morbidities, 2005 Figure 31: Breakdown of drug therapy in the diagnosed dyslipidemia sub-populations in Italy, 2005 Figure 32: Breakdown of statin therapy by compound, line of therapy, daily dose and use of brands versus generics in Italy, for the overall drug treated dyslipidemia population, 2005 Figure 33: Breakdown of first- and second-line therapy by antidyslipidemic drug class in Italy for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 34: Segmentation of drug-treated overall dyslipidemia population having therapy changed over a one-year period in Italy for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 35: Breakdown of combination therapy by dyslipidemia sub-population in Italy, 2005 Figure 36: Breakdown of treatment outcomes by dyslipidemia sub-population in Italy, 2005 Figure 37: Breakdown of the overall dyslipidemia population in Spain by diagnosis, type of dyslipidemia, disease severity and prevalence of risk factors and co-morbidities, 2005 Figure 38: Breakdown of drug therapy in the diagnosed dyslipidemia sub-populations in Spain, 2005 Figure 39: Breakdown of statin therapy by compound, line of therapy, daily dose and use of brands versus generics in Spain, for the overall drug treated dyslipidemia population, 2005 Figure 40: Breakdown of first- and second-line therapy by antidyslipidemic drug class in Spain for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 41: Segmentation of drug-treated overall dyslipidemia population having therapy changed over a one-year period in Spain for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 42: Breakdown of combination therapy by dyslipidemia sub-population in Spain, 2005 Figure 43: Breakdown of treatment outcomes by dyslipidemia sub-population in Spain, 2005 Figure 44: Breakdown of the overall dyslipidemia population in the UK by diagnosis, type of dyslipidemia, disease severity and prevalence of risk factors and co-morbidities, 2005 Figure 45: Breakdown of drug therapy in the diagnosed dyslipidemia sub-populations in the UK, 2005 Figure 46: Breakdown of statin therapy by compound, line of therapy, daily dose and use of brands versus generics in the UK, for the overall drug treated dyslipidemia population, 2005 Figure 47: Breakdown of first- and second-line therapy by antidyslipidemic drug class in the UK for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 48: Segmentation of drug-treated overall dyslipidemia population having therapy changed over a one-year period in the UK for the overall diagnosed and drug treated dyslipidemia population, 2005 Figure 49: Breakdown of combination therapy by dyslipidemia sub-population in the UK, 2005 Figure 50: Breakdown of treatment outcomes by dyslipidemia sub-population in the UK, 2005 Figure 51: Proportion of diagnosed dyslipidemia patients with each type of dyslipidemia in the seven major markets, 2005 Figure 52: Proportion of diagnosed hypercholesterolemia patients with familial hypercholesterolemia in the seven major markets, 2005 Figure 53: Proportion of diagnosed dyslipidemia patients with low HDL cholesterol in the seven major markets, 2005 Figure 54: Breakdown of the diagnosed dyslipidemia population by disease severity in the seven major markets, 2005 Figure 55: Estimated proportion of dyslipidemia patients in the general population diagnosed in the seven major markets, 2005 Figure 56: Overview of NCEP ATP III guidelines Figure 57: Breakdown of statin prescribing by type of statin in overall dyslipidemia patients in the seven major markets, 2005 Figure 58: Brand versus generic prescribing of statins, currently and in three years, 2005 Figure 59: Proportion of drug-treated dyslipidemia patients unable to tolerate statin therapy in the seven major markets, 2005 Figure 60: Proportion of drug-treated dyslipidemia patients refusing to take statin therapy in the seven major markets, 2005 Figure 61: Proportion of dyslipidemia patients on statin therapy that are refractory to statins in the seven major markets, 2005 Figure 62: Breakdown of fibrate prescribing by compound in overall dyslipidemia patients in the seven major markets, 2005 Figure 63: Proportion of overall drug-treated dyslipidemia patients progressing to second-line therapy, 2005 Figure 64: Comparison of antidyslipidemic drug classes at first- versus second-line in the combined seven markets, 2005 Figure 65: Proportion of overall drug-treated dyslipidemia patients on second-line therapy progressing to third-line therapy and beyond, 2005 Figure 66: Proportion of overall drug-treated dyslipidemia patients having their therapy changed over a one-year period, 2005 Figure 67: Reasons for change in antidyslipidemic therapy in the seven major markets, 2005 Figure 68: Type of changes in antidyslipidemic therapy in the seven major markets, 2005 Figure 69: Proportion of overall drug-treated dyslipidemia patients receiving combination therapy in the seven major markets, 2005 Figure 70: Proportion of hypercholesterolemia drug-treated dyslipidemia patients receiving combination therapy in the seven major markets, 2005 Figure 71: Proportion of drug-treated mixed dyslipidemia patients receiving combination therapy in the seven major markets, 2005 Figure 72: Proportion of drug-treated diabetic dyslipidemia patients receiving combination therapy in the seven major markets, 2005 Figure 73: Proportion of drug-treated dyslipidemia patients in each sub-population receiving a statin + ezetimibe combination in the seven major markets, 2005 Figure 74: Proportion of drug-treated dyslipidemia patients in each sub-population receiving a statin + fibrate combination in the seven major markets, 2003 Figure 75: Unmet needs in the dyslipidemia market, 2005 Figure 76: Physician awareness of ezetimibe, 2005 Figure 77: Proportion of patients expected to be prescribed ezetimibe, 2005 Figure 78: Proportion of physicians aware of Vytorin, 2005 Figure 79: Proportion of patients estimated to receive Vytorin, 2005 Figure 80: Physician awareness of atorvastatin + torcetrapib, 2005 Figure 81: Proportion of patients expected to receive atorvastatin + torcetrapib when launched, 2005 AbstractIntroductionDatamonitor estimates that there are 267m people in the seven major markets with total cholesterol >200mg/dL which is set to rise to 287m in 2015. Despite this vast patient potential, low diagnosis rates limit the market size, and with the launch of generic statins, and the maturing of the market, it is increasingly important for companies to target the under-treated dyslipidemia sub-populations. Scope
Dyslipidemia patients are often plagued with risk factors and co-morbidities that increase their relative risk considerably. Datamonitor research found that a high percentage of patients with dyslipidemia also suffer from obesity, hypertension and type 2 diabetes, representing a potentially lucrative target. The more aggressive approach to LDL lowering, and lower treatment thresholds recommended in updated guidelines means a greater patient population. However, increasing awareness in physicians and in the general population is essential to increase diagnosis and thus treatment rates. Physicians predict that combination therapy will play an increasingly important role over the next three years. Given the highly competitive nature of the antidyslipidemic market, companies that can position novel products as effective treatments for use in combination therapy are likely to be the most successful. Reasons to Purchase
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||